67 The Impact of Oral Chronic Graft-Versus-Host Disease on Global Measures of Quality of Life

Track: BMT Tandem "Scientific" Meeting
Saturday, February 14, 2015, 4:45 PM-6:45 PM
Seaport Ballroom ABC (Manchester Grand Hyatt)
Joseph DePalo , Harvard School of Dental Medicine, Boston, MA
Xiaoyu Chai, MS , Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
Stephanie J. Lee, MD, MPH , Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
Corey S. Cutler, MD , Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
Nathaniel Treister, DMD, DMSc , Division of Oral Medicine and Dentistry, Brigham and Women's Hospital, Boston, MA
Chronic GVHD (cGVHD) is a frequent complication of allogeneic hematopoietic stem cell transplantation (HSCT) and affects multiple organ systems, with the oral cavity being one of the most frequently affected sites.  Patients with cGVHD experience reduced quality of life (QOL), yet the specific impact of oral cGVHD on QOL is poorly understood.  The objective of this study was to characterize the impact of oral cGVHD on global measures of QOL.  METHODS:  QOL data were collected using the FACT-BMT and SF-36 instruments for 569 patients enrolled in the Chronic GVHD Consortium, with a total of 1,915 follow-up visits.  At study enrollment, patients were categorized as isolated oral cGVHD (n=22), oral and concomitant extra-oral cGVHD (n=420), and only extra-oral cGVHD (n=127).  Utilizing all longitudinal data, QOL scores were compared using a multivariable linear model controlling for demographic, transplant, and cGVHD characteristics.  RESULTSPatients with isolated oral cGVHD reported better physical well-being (P=0.009), BMT well-being (P=0.01), and decreased bodily pain (P=0.01) compared to patients with oral and concomitant extra-oral cGVHD.  A similar trend was observed that patients with isolated oral cGVHD reported better physical well-being (P=0.02) and less bodily pain (P=0.02) compared to patients with only extra-oral cGVHD.  QOL scores were similar in several domains, most notably social/family well-being, physical role functioning, and vitality, when comparing patients with isolated oral cGVHD to patients with oral and concomitant extra-oral cGVHD and only extra-oral cGVHD.  CONCLUSIONS:  Isolated oral cGVHD is associated with better QOL compared to extra-oral cGVHD across multiple domains, in particular physical well-being and bodily pain.         Multivariable analysis comparing quality of life scores
    Isolated oral vs. oral and extra-oral Isolated oral vs. only extra-oral
    difference in QOL scores between groups p-value difference in QOL scores between groups p-value
FACT-BMT          
  total 3.14 0.03 1.58 0.32
  physical well-being 1.09 0.009 1.09 0.02
  social/family well-being 0.17 0.63 -0.13 0.75
  emotional well-being 0.45 0.14 0.07 0.85
  functional well-being 0.88 0.05 0.29 0.56
  BMT well-being 1.10 0.01 0.81 0.10
SF-36          
  PCS 1.20 0.14 1.08 0.23
  MCS 0.17 0.85 -0.67 0.50
  physical functioning 0.96 0.25 0.79 0.39
  physical role functioning -0.29 0.76 -0.52 0.62
  bodily pain 2.26 0.01 2.43 0.02
  general health perceptions 1.62 0.05 0.22 0.81
  vitality 0.07 0.94 -0.50 0.60
  social role functioning 1.29 0.21 0.81 0.47
  emotional role functioning 0.46 0.67 -0.72 0.54
  mental health 0.27 0.75 -0.43 0.64
BMT= bone marrow transplant.  PCS= physical component score.  MCS= mental component score.

 

Disclosures:
Nothing To Disclose